This paper reviews new drug targets in the treatment of depression and new drug candidates to treat depression. Depression is characterized by aberrations
INTRANASAL medicationDepression is a severe mental health problem that affects people regardless of social status or education, is associated with changes in mood and behavior, and can result in a suicide attempt. Therapy of depressive disorders is based mainly on drugs discovered in...
Due to the growing gap between the demand and supply of therapeutic services for people suffering from depression, with this study, we are investigating the effectiveness and factors of influence of new approaches in group treatments for depression. Two previous studies have already identified boulderin...
Postpartum depression is a major form of depression, and the effects of fluctuations in neurosteroid levels on the expression of gamma-aminobutyric acid (GABA)Areceptors are thought to play a role in its pathogenesis (Gunduz-Bruce et al.2022). Therefore, GABA modulators have been investigated in...
The primary outcome measures are changes in CSF Aβ40 and Aβ42 levels, vascular dysfunction biomarker levels, and scores of the Montgomery–Asberg Depression Ratio Scale at week 8. Sodium oligomannate (GV-971), a marine-derived oligosaccharide, can reconstitute the gut microbiota, reduce ...
Postpartum depression can be treated with a combination of therapy and other antidepressants. But Zurzuvae is only the second medication, and the first pill, that the FDA has approved specifically for the condition. The first approved drug, brexanolone, also made by Sage Therapeutics, under th...
A chronic brain disorder that is characterized by partial or generalized spontaneous (unprovoked) recurrent epileptic seizures and, often, comorbidities such as anxiety and depression. Epileptogenesis The gradual process by which normal brain tissue becomes epileptic, encompassing the events in the latent...
Back in 2022, the FDA granted Abbott Breakthrough Device designation for deep brain stimulation (DBS) for treatment-resistant depression (TRD), a form of major depressive disorder. Now Abbott announced it has initiated a pivotal clinical trial, called the TRANSCEND study, to evaluate the use of...
oxalate is associated with the normalization of AD biomarkers in CSF and inflammatory markers in the peripheral blood. The primary outcome measures are changes in CSF Aβ40 and Aβ42 levels, vascular dysfunction biomarker levels, and scores of the Montgomery–Asberg Depression Ratio Scale at week ...
The reproductive hormone oxytocin facilitates labour, birth and postpartum adaptations for women and newborns. Synthetic oxytocin is commonly given to induce or augment labour and to decrease postpartum bleeding. To systematically review studies measurin